Bendamustine (Levact®)

Assessment Status NCPE Assessment Process Complete
Drug Bendamustine
Brand Levact®
Indication Treatment of Chronic Lymphocytic Leukaemia (CLL)
Assessment Process
Rapid review commissioned 01/03/2011
Rapid review completed 21/03/2011
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 08/03/2012
NCPE assessment completed 20/11/2012
NCPE assessment outcome Reimbursement recommended

The NCPE  recommends reimbursement of bendamustine (Levact®) for patients unable to tolerate fludarabine/cyclophosphamide.

Technical Summary